Bank of New York Mellon
TELO icon

Bank of New York Mellon’s Telomir Pharmaceuticals TELO Stock Holding History

Bank of New York Mellon’s Portfolio TELO Stock Details TELO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$65.9K Hold
51,454
– – ﹤0.01% 4222
2026
Q1 		$66.9K Hold
51,454
– – ﹤0.01% 4128
2025
Q4 		$68.4K Hold
51,454
– – ﹤0.01% 4131
2025
Q3 		$71.5K Buy
51,454
+1
+0% +$2 ﹤0.01% 4116
2025
Q2 		$64.3K Sell
51,453
-39,900
-44% -$92.2K ﹤0.01% 4079
2025
Q1 		$295K Buy
91,353
+19,058
+26% +$83.3K ﹤0.01% 3709
2024
Q4 		$298K Buy
72,295
+20,931
+41% +$98.6K ﹤0.01% 3788
2024
Q3 		$330K Buy
51,364
+1,199
+2% +$5.84K ﹤0.01% 3718
2024
Q2 		$241K Buy
+50,165
New +$313K ﹤0.01% 3897

Other funds holding TELO

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $11.8B AUM 21.23% 1-Year Est. Return
PWM
Praetorian Wealth Management Carmel, California $580M AUM 19.43% 1-Year Est. Return
MCM
Morton Capital Management Calabasas, California $731M AUM 20.62% 1-Year Est. Return
CA
Clearstead Advisors Cleveland, Ohio $10.6B AUM 24.87% 1-Year Est. Return
NAM
NorthCrest Asset Manangement Plymouth, Minnesota $3.89B AUM 40.33% 1-Year Est. Return
KPWS
Kestra Private Wealth Services Austin, Texas $9.1B AUM 32.09% 1-Year Est. Return
RFC
Regions Financial Corp Birmingham, Alabama $16.8B AUM 26.68% 1-Year Est. Return

Bank of New York Mellon's TELO Position: Q2 2026 in Review

Bank of New York Mellon held its Telomir Pharmaceuticals (TELO) position steady in Q2 2026 at 51,454 shares worth $65.9K. The position accounts for ﹤0.01% of the portfolio, ranked #4222.

Bank of New York Mellon first reported a position in TELO in Q2 2024 and has held it in 9 quarters since. The position peaked at $330K in Q3 2024. 15 funds tracked by Wall St. Rank hold TELO as of Q2 2026.

  • Bank of New York Mellon held 51,454 shares of Telomir Pharmaceuticals worth $65.9K as of Q2 2026.
  • Bank of New York Mellon left its Telomir Pharmaceuticals share count unchanged in Q2 2026.
  • Telomir Pharmaceuticals made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #4222 holding.
  • Bank of New York Mellon first reported a position in Telomir Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
  • Bank of New York Mellon's Telomir Pharmaceuticals position peaked at $330K in Q3 2024.
  • 15 funds tracked by Wall St. Rank held Telomir Pharmaceuticals as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.